Cell MedX Corp.
CMXC · OTC
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.26 | -0.09 | -10.12 | -0.04 |
| FCF Yield | -1.30% | -0.89% | -0.37% | -0.20% |
| EV / EBITDA | 0.00 | 109.98 | 0.00 | -66.90 |
| Quality | ||||
| ROIC | 0.00% | -24.54% | 0.00% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.41 | 0.35 | 0.19 | 0.12 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -49.81% | -140.83% | -81.46% | 27.92% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -0.20 | 0.00 | -2.46 |
| Interest Coverage | 0.00 | 4.18 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |